3D printed vasculogenic pectin-fucoidan scaffold containing sildenafil-loaded nanomicelles promoted diabetic wound healing
Abstract
Chronic diabetic wounds are marked by impaired angiogenesis, persistent inflammation, and delayed tissue regeneration, making them a critical challenge in clinical practice. Effective healing requires biomaterials that restore vascularization and support cell proliferation and growth. In this context, a 3D-printed scaffold composed of pectin (Pec) and fucoidan (Fc) was fabricated and integrated with sildenafil-loaded nanomicelles (Sf.NMs). Due to the hydrophobic nature of sildenafil, encapsulation in nanomicelles was employed to improve aqueous dispersion and enable controlled release. Scaffold fabrication was carried out using extrusion-based 3D printing, an accessible technique that facilitates bioactive agent incorporation at room temperature. Physicochemical evaluation demonstrated a swelling ratio of 278.1 ± 15.0 % in water and a biodegradation rate of 39.2 ± 2.0 % in PBS after 7 days. Drug release studies showed a sustained profile, reaching 94.7 ± 2.5 % over 11 days. Cytotoxicity assays confirmed well biocompatibility and cell adhesion on the scaffolds. Additionally, the sustained release of sildenafil significantly stimulated angiogenesis in the CAM assay. In vivo evaluation in a diabetic rat wound model revealed reduced inflammation, enhanced re-epithelialization, and improved wound closure. These results highlight the Pec-Fc/Sf.NMs scaffold as a promising biomaterial capable of addressing impaired vascularization and promoting tissue repair in diabetic wound…
Read the paper
Related studies
- 2024 update in heart failure
- Vascular involvement in idiopathic pulmonary fibrosis
- A novel technique- subendometrial autologous platelet rich plasma injection in patients with unresponsive thin endometrium undergoing frozen-thawed embryo transfer: a prospective cohort study
- Does metformin prolong pregnancy in preterm pre-eclampsia? A study protocol for a South African, hospital-based double-blind, randomised, placebo-controlled trial
- Combined Pulmonary Fibrosis and Emphysema (CPFE): A "New" Smoking-Related Interstitial Lung Disease (ILD)
- Impact of an acute 1-month cannabidiol treatment on pain and inflammation after a long bone fracture: a triple-blind randomised, placebo-controlled, clinical trial protocol
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.